Major Adverse Cardiovascular Events (MACE)

Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial

by Prateek Chopra | July 5, 2026 | Diabetes Conferences | ADA 2026 Mechanistic Insights Methods Key Findings Protein-Specific Effects Clinical Implications Four circulating proteins—THBS2, NPPB, ANGPT2, and CD93—mediated a substantial proportion of semaglutide’s cardiovascular benefit independent of weight loss. These findings provide new insights into the biological mechanisms underlying semaglutide’s cardioprotective effects.

Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial Read Post »

Leave a Comment / Diabetes Conferences / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiovascular Disease, GLP-1 Receptor Agonists, Major Adverse Cardiovascular Events (MACE), SELECT Trial, Semaglutide

Effect of Different Treatment Durations of Sodium–Glucose Cotransporter2 Inhibitor on Cardiovascular Outcomes in Patients with Type 2 Diabetes:A Target Trial Emulation Study

by Prateek Chopra | July 4, 2026 | Diabetes Conferences | ADA 2026 Clinical Background Methods Study Population Key Findings Clinical Implications In this large nationwide analysis, longer SGLT2i treatment duration was associated with progressively greater reductions in major adverse cardiovascular events and hospitalization for heart failure, supporting sustained therapy to optimize cardiovascular outcomes in patients with type 2 diabetes.

Effect of Different Treatment Durations of Sodium–Glucose Cotransporter2 Inhibitor on Cardiovascular Outcomes in Patients with Type 2 Diabetes:A Target Trial Emulation Study Read Post »

Leave a Comment / Diabetes Conferences / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiovascular Outcomes, Heart Failure Hospitalization, Major Adverse Cardiovascular Events (MACE), SGLT2 Inhibitors, Type 2 Diabetes (T2DM)